SSSW(SH:688399) Zheng Quan Ri Bao·2026-01-30 23:37Core Viewpoint - The company anticipates a significant increase in losses for the fiscal year 2025 compared to the previous year, with projected net losses ranging from 29.4 million to 44 million yuan [2][4]. Financial Performance Forecast - The estimated net profit attributable to the parent company for 2025 is projected to be between -29.4 million and -44 million yuan, representing an increase in losses of 27.4 million to 41.99 million yuan compared to the previous year [2][4]. - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is forecasted to be between -81.9 million and -122.8 million yuan, indicating an increase in losses of 10.06 million to 50.96 million yuan compared to the previous year [2][4]. Previous Year Performance - In 2024, the company reported a total profit of 4.1872 million yuan, with a net loss attributable to the parent company of -200.17 million yuan. The net profit excluding non-recurring gains and losses was -71.8371 million yuan [6]. Reasons for Performance Changes - The increase in losses is attributed to intensified industry competition and ongoing medical procurement policies, which have led to a decrease in revenue from self-produced diagnostic test products due to a VAT adjustment to 13% [7]. - The company has made efforts to reduce long-term accounts receivable, resulting in a decrease in the balance of such receivables [7]. - The company has recognized impairment provisions for various assets based on prudence principles, in accordance with accounting standards [7]. - There has been a reduction in government subsidies received during the reporting period [8]. - Despite a decrease in R&D spending, the company maintains a relatively high intensity of R&D investment, focusing on core product lines and enhancing overall solution capabilities [9].